Romero, AlejandroRamos, EvaPatiño, PalomaOset-Gasque, Maria JLopez-Muñoz, FranciscoMarco-Contelles, JoseAyuso, María IAlcazar, Alberto2023-01-252023-01-252016-11-23Romero A, Ramos E, Patiño P, Oset-Gasque MJ, López-Muñoz F, Marco-Contelles J, et al. Melatonin and Nitrones As Potential Therapeutic Agents for Stroke. Front Aging Neurosci. 2016 Nov 23;8:281.1663-4365http://hdl.handle.net/10668/11259Stroke is a disease of aging affecting millions of people worldwide, and recombinant tissue-type plasminogen activator (r-tPA) is the only treatment approved. However, r-tPA has a low therapeutic window and secondary effects which limit its beneficial outcome, urging thus the search for new more efficient therapies . Among them, neuroprotection based on melatonin or nitrones, as free radical traps, have arisen as drug candidates due to their strong antioxidant power . In this Perspective article, an update on the specific results of the melatonin and several new nitrones are presented.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/melatoninneuroprotectionnitronesoxidative stressstrokeTissue Plasminogen ActivatorAntioxidantsMelatoninnitronesNeuroprotectionStrokeAgingFree Radicalsresearch article27932976open accessTerapéuticaMelatoninaEnfermedadAntioxidantesRadicales LibresEnvejecimientoNeuroprotección10.3389/fnagi.2016.00281PMC5120103https://www.frontiersin.org/articles/10.3389/fnagi.2016.00281/pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120103/pdf